Warburg effect's manifestation in aggressive pheochromocytomas and paragangliomas: Insights from a mouse cell model applied to human tumor tissue

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Fliedner, Stephanie M J ^a,i   Kaludercic, Nina ^b   Jiang, Xiao Sheng ^a   Hansikova, Hana ^c   Hajkova, Zuzana ^c   Sladkova, Jana ^c   Limpuangthip, Andrea ^a   Backlund, Peter S ^a   Wesley, Robert ^d   Martiniova, Lucia ^a   Jochmanova, Ivana ^a,e   Lendvai, Nikoletta K ^a   Breza, Jan ^f   Yergey, Alfred L ^a   Paolocci, Nazareno ^b,g   Tischler, Arthur S ^h   Zeman, Jiri ^c   Porter, Forbes D ^a   Lehnert, Hendrik ⁱ   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e P J AFÁRIK UNIVERSITY   (Slovakia)

^f Faculty of Medicine of Comenius University and University Hospital Bratislava   (Slovakia)

^g UNIVERSITY OF PERUGIA   (Italy)

^h TUFTS MEDICAL CENTER   (United States)

ⁱ UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE TRANSPORTER 1; HEXOKINASE; HEXOKINASE 2; LACTATE DEHYDROGENASE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE B; UBIQUINOL CYTOCHROME C REDUCTASE; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; CANCER CELL; CANCER MODEL; CANCER TISSUE; CHILD; CITRIC ACID CYCLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION; GLYCOLYSIS; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARAGANGLIOMA; PATHOGENESIS; PHEOCHROMOCYTOMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; SCHOOL CHILD; UPREGULATION; VON HIPPEL LINDAU DISEASE;

ADRENAL GLAND NEOPLASMS; ADRENAL MEDULLA; ANIMALS; CELL LINE, TUMOR; ELECTRON TRANSPORT COMPLEX I; ELECTRON TRANSPORT COMPLEX II; ELECTRON TRANSPORT COMPLEX III; ELECTRON TRANSPORT COMPLEX IV; GENE EXPRESSION; GLYCOLYSIS; HUMANS; L-LACTATE DEHYDROGENASE; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROTEOME; REACTIVE OXYGEN SPECIES;

EID: 84864421791     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040949     Document Type: Article

References (70)

1. Hsu PP, Sabatini DM, ((2008)) Cancer cell metabolism: Warburg and beyond. Cell 134:: 703--707.
2. Gatenby RA, Gillies RJ, ((2008)) A microenvironmental model of carcinogenesis. Nat Rev Cancer 8:: 56--61.
3. Vazquez A, Liu J, Zhou Y, Oltvai ZN, ((2010)) Catabolic efficiency of aerobic glycolysis: The Warburg effect revisited. BMC Syst Biol 4:: 58.
4. Gillies RJ, Robey I, Gatenby RA, ((2008)) Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 49 Suppl 2: 24S--42S.
5. Baysal BE, ((2008)) Clinical and molecular progress in hereditary paraganglioma. J Med Genet 45:: 689--694.
6. Sudarshan S, Sourbier C, Kong HS, Block K, Valera Romero VA, et al. ((2009)) Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. Mol Cell Biol 29:: 4080--4090.
7. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno-Sanchez R, ((2010)) The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation- why mitochondria are targets for cancer therapy. Mol Aspects Med 31:: 145--170.
8. Jung SN, Yang WK, Kim J, Kim HS, Kim EJ, et al. ((2008)) Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 29:: 713--721.
9. Chi JT, Wang Z, Nuyten DS, Rodriguez EH, Schaner ME, et al. ((2006)) Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 3:: e47.
10. Qing G, Simon MC, ((2009)) Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev 19:: 60--66.
11. Baysal BE, Ferrell RE, Willett-Brozick JE, Lawrence EC, Myssiorek D, et al. ((2000)) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287:: 848--851.
12. Niemann S, Muller U, ((2000)) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26:: 268--270.
13. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, et al. ((2001)) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:: 49--54.
14. Burnichon N, Briere JJ, Libe R, Vescovo L, Riviere J, et al. ((2010)) SDHA is a tumor suppressor gene causing paraganglioma. Hum Mol Genet 19:: 3011--3020.
15. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, et al. ((2002)) Functional consequences of a SDHB gene mutation in an apparently sporadic pheochromocytoma. J Clin Endocrinol Metab 87:: 4771--4774.
16. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, et al. ((2009)) The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One 4:: e7094.
17. Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, et al. ((2001)) The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 69:: 1186--1197.
18. Douwes Dekker P, Hogendoorn P, Kuipers-Dijkshoorn N, Prins F, van Duinen S, et al. ((2003)) SDHD mutations in head and neck paragangliomas result in destabilization of complex II in the mitochondrial respiratory chain with loss of enzymatic activity and abnormal mitochondrial morphology. The Journal of Pathology 201:: 480--486.
19. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, et al. ((2005)) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:: 2231--2239.
20. Guzy RD, Sharma B, Bell E, Chandel NS, Schumacker PT, ((2008)) Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis. Mol Cell Biol 28:: 718--731.
21. Dahia PL, ((2006)) Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann N Y Acad Sci 1073:: 208--220.
22. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. ((1999)) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:: 271--275.
23. Kaelin WG Jr, ((2002)) Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2:: 673--682.
24. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, et al. ((2003)) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:: 5615--5621.
25. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, et al. ((2004)) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. Jama 292:: 943--951.
26. Amar L, Bertherat J, Baudin E, Ajzenberg C, Bressac-de Paillerets B, et al. ((2005)) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23:: 8812--8818.
27. Timmers HJ, Kozupa A, Eisenhofer G, Raygada M, Adams KT, et al. ((2007)) Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 92:: 779--786.
28. Srirangalingam U, Khoo B, Walker L, MacDonald F, Skelly RH, et al. ((2009)) Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer 16:: 515--525.
29. Powers JF, Evinger MJ, Zhi J, Picard KL, Tischler AS, ((2007)) Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile. Neuroscience 147:: 928--937.
30. Lai EW, Joshi BH, Martiniova L, Dogra R, Fujisawa T, et al. ((2009)) Overexpression of interleukin-13 receptor-alpha2 in neuroendocrine malignant pheochromocytoma: a novel target for receptor directed anti-cancer therapy. J Clin Endocrinol Metab 94:: 2952--2957.
31. Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, et al. ((2009)) Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis 26:: 239--250.
32. Smith EH, Janknecht R, Maher LJ III, ((2007)) Succinate inhibition of {alpha}-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 16:: 3136--3148.
33. Goffrini P, Ercolino T, Panizza E, Giache V, Cavone L, et al. ((2009)) Functional study in a yeast model of a novel succinate dehydrogenase subunit B gene germline missense mutation (C191Y) diagnosed in a patient affected by a glomus tumor. Hum Mol Genet 18:: 1860--1868.
34. Huang J, Lemire BD, ((2009)) Mutations in the C. elegans succinate dehydrogenase iron-sulfur subunit promote superoxide generation and premature aging. J Mol Biol 387:: 559--569.
35. Gatenby RA, Gillies RJ, ((2004)) Why do cancers have high aerobic glycolysis? Nat Rev Cancer 4:: 891--899.
36. Granchi C, Bertini S, Macchia M, Minutolo F, ((2010)) Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem 17:: 672--697.
37. McCarty MF, Whitaker J, ((2010)) Manipulating tumor acidification as a cancer treatment strategy. Altern Med Rev 15:: 264--272.
38. Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, et al. ((1997)) Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 150:: 409--415.
39. Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, et al. ((2001)) Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51:: 349--353.
40. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, et al. ((2000)) High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 60:: 916--921.
41. Thorn CC, Freeman TC, Scott N, Guillou PJ, Jayne DG, ((2009)) Laser microdissection expression profiling of marginal edges of colorectal tumours reveals evidence of increased lactate metabolism in the aggressive phenotype. Gut 58:: 404--412.
42. Fantin VR, St-Pierre J, Leder P, ((2006)) Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9:: 425--434.
43. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, et al. ((2010)) Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 107:: 2037--2042.
44. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, et al. ((2009)) LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther 8:: 626--635.
45. Slane BG, Aykin-Burns N, Smith BJ, Kalen AL, Goswami PC, et al. ((2006)) Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res 66:: 7615--7620.
46. Piantadosi CA, Suliman HB, ((2008)) Transcriptional Regulation of SDHa flavoprotein by nuclear respiratory factor-1 prevents pseudo-hypoxia in aerobic cardiac cells. J Biol Chem 283:: 10967--10977.
47. Szeto SSW, Reinke SN, Sykes BD, Lemire BD, ((2007)) Ubiquinone-binding Site Mutations in the Saccharomyces cerevisiae Succinate Dehydrogenase Generate Superoxide and Lead to the Accumulation of Succinate. J Biol Chem 282:: 27518--27526.
48. Zhao Z, Rothery RA, Weiner JH, ((2006)) Effects of site-directed mutations in Escherichia coli succinate dehydrogenase on the enzyme activity and production of superoxide radicals. Biochem Cell Biol 84:: 1013--1021.
49. Bacsi A, Woodberry M, Widger W, Papaconstantinou J, Mitra S, et al. ((2006)) Localization of superoxide anion production to mitochondrial electron transport chain in 3-NPA-treated cells. Mitochondrion 6:: 235--244.
50. Guo J, Lemire BD, ((2003)) The ubiquinone-binding site of the Saccharomyces cerevisiae succinate-ubiquinone oxidoreductase is a source of superoxide. J Biol Chem 278:: 47629--47635.
51. Cervera AM, Apostolova N, Crespo FL, Mata M, McCreath KJ, ((2008)) Cells silenced for SDHB expression display characteristic features of the tumor phenotype. Cancer Res 68:: 4058--4067.
52. Silkin Y, Oyedotun KS, Lemire BD, ((2007)) The role of Sdh4p Tyr-89 in ubiquinone reduction by the Saccharomyces cerevisiae succinate dehydrogenase. Biochim Biophys Acta 1767:: 143--150.
53. Selak MA, Duran RV, Gottlieb E, ((2006)) Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells. Biochim Biophys Acta 1757:: 567--572.
54. Owens KM, Aykin-Burns N, Dayal D, Coleman MC, Domann FE, et al. ((2012)) Genomic instability induced by mutant succinate dehydrogenase subunit D (SDHD) is mediated by O2(-*) and H2O2. Free Radic Biol Med 52:: 160--166.
55. Pani G, Galeotti T, Chiarugi P, ((2010)) Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 29:: 351--378.
56. Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, et al. ((2007)) Manganese superoxide dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res 67:: 10260--10267.
57. Hempel N, Carrico PM, Melendez JA, ((2011)) Manganese superoxide dismutase (Sod2) and redox-control of signaling events that drive metastasis. Anticancer Agents Med Chem 11:: 191--201.
58. Pani G, Colavitti R, Bedogni B, Fusco S, Ferraro D, et al. ((2004)) Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr Med Chem 11:: 1299--1308.
59. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, et al. ((2011)) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208:: 313--326.
60. Semenza GL, ((2007)) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39:: 231--234.
61. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, et al. ((2009)) Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res 15:: 6378--6385.
62. Fliedner SM, Breza J, Kvetnansky R, Powers JF, Tischler AS, et al. ((2010)) Tyrosine hydroxylase, chromogranin A, and steroidogenic acute regulator as markers for successful separation of human adrenal medulla. Cell Tissue Res 340:: 607--612.
63. Jiang X-S, Tang L-Y, Cao X-J, Zhou H, Xia Q-C, et al. ((2005)) Two-dimensional gel electrophoresis maps of the proteome and phosphoproteome of primitively cultured rat mesangial cells. Electrophoresis 26:: 4540--4562.
64. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS, ((1999)) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:: 3551--3567.
65. Nelson TJ, Backlund PSJ, Yergey AL, Alkon DL, ((2002)) Isolation of protein subpopulations undergoing protein-protein interactions. Mol Cell Proteomics 1:: 253--259.
66. Keller A, Nesvizhskii AI, Kolker E, Aebersold R, ((2002)) Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 74:: 5383--5392.
67. Nesvizhskii AI, Keller A, Kolker E, Aebersold R, ((2003)) A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 75:: 4646--4658.
68. Rickwood D, Wilson M, Darley-Usmar V, ((1987)) Isolation and characteristics of intact mitochondria. In: Darley-Usmar V, Rickwood D, Wilson M, editors. Mitochondria: A Practical Approach Oxford, U.K.: IRL Press pp. pp. 1--16.
69. Rustin P, Chretien D, Bourgeron T, Gerard B, Rotig A, et al. ((1994)) Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 228:: 35--51.
70. Carpi A, Menabo R, Kaludercic N, Pelicci P, Di Lisa F, et al. ((2009)) The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. Biochim Biophys Acta 1787:: 774--780.